Index

ADL (Activities of Daily Living), 131–132
Admiral Nurse (AN) services, 119, 120
ADRQL, 83, 84
ALS. See Amyotrophic lateral sclerosis (ALS)
ALSAQ-5, 46–47
ALSAQ-40, 44–46, 50–51, 171, 180–181
ALS CARE programme, 44
ALS Functional Rating Scale (ALSFRS, ALSFRS-R), 42, 46, 180
ALS-Specific Quality of Life Instrument (ALSSQoL), 178–179, 180, 184
Alzheimer’s disease. See also Dementia, QoL measurement in
clinical features of, 175
QoL instrument comparison, 181–182
QoL measurement, challenges in,
175–176
SEIQoL-DW data, 181–182
SF-36 data, 116, 117
ZBI data, 130–131
Amyotrophic lateral sclerosis (ALS)
ALSAQ-5, 46–47
ALSAQ-40, 44–46, 50–51, 171, 180–181
clinical assessment of, 41–42
clinical features of, 175
health status generic measures, 42–44
Neuro-QoL Initiative, 76f, 77
overview, 41
QoL instrument comparison, 180–181
QoL measurement, challenges in, 175–176
SEIQoL-DW data, 44, 179, 180, 184
SF-36 data, 42–43, 116, 180–181
SIP data, 43–44, 180
Andrich, D., 151–152
Ankri, J., 127
Appel Scale, 42, 43
Arthritis Impact Measurement Scales (AIMS), 3–4
Bachner, Y. G., 125–126
BASQUID, 83, 84t, 87
Baumgarten Behaviour Disturbance questionnaire, 131
Beck Depression Inventory (BDI)
caregiver burden assessment, 115, 132
multiple system atrophy, 61
Bedard, M., 127, 133
Before-after comparison analysis, 7
Behavioral Disturbances Scale, 131
BI (Burden Interview). See Zarit Burden Interview (ZBI)
Birnbaum, A., 150
BIS (Burden Interview Scale). See Zarit Burden Interview (ZBI)
Björnson, K. F., 99
Blessed Dementia Scale, 132
Boyer, E., 133
Brief Symptoms Inventory, 130–131
Brislin, R. W., 144
Brod, M., 88
Brogden, H., 150
Bulpitt, C., 11
Burden of Caregiver Index, 120
Calne, S., 13
Campbell, N., 154
Cannabis in Multiple Sclerosis (CAMS) trial, 154–162, 155t,
156f, 157t, 158f, 160f, 161f
Carbidopa-Levodopa, 12
Caregiver Burden Scale, 120
Carer burden
Admiral Nurse (AN) services, 119, 120
BDI assessment of, 115, 132
Burden of Caregiver Index, 120
Caregiver Burden Scale, 120
caring variables, 129
child self-report vs. parent-proxy report, cerebral palsy, 97–98
definitions, 114
dementia, QoL measurement in, 120, 128, 130
dementia, QoL reporting by, 83–88, 176
DEMQoL evaluation of, 84t, 87, 88–90
depression in, 132
Elmstahl questionnaire, 121
ethnicity, country burden differences, 128
family relationship data, 128–129
generic measures generally, 114–115
GHQ assessment, 114–115, 117–120, 118t
health status, quality of life in, 129–130
illness severity data, 130–131
Impact of Caregiving Scale, 126
outcome measures generally, 115, 120–121, 133–134
Parkinson’s disease, 120, 130, 131
patient behavior, 131–132
patient mental state data, 132
PIXEL, 121
SF-36, 114–115, 117, 133–134
social support data, 129
stroke, 119
type of condition data, 130
WHOQoL, 114–115
Zarit Burden Interview (ZBI). See Zarit Burden Interview (ZBI)
Carer Strain Index (CSI), 114
Carr, A. J., 83
CBI (Carer Burden Inventory). See Zarit Burden Interview (ZBI)
CBS, 84t
Center for Epidemiologic Studies Depression Scale (CED-S), 133
Cerebral palsy
child self-report vs. parent-proxy report, 97–98
CPCHILD, 98, 102t
CP QoL-Child, 99–101, 102t
DISABKIDS CP Disease Module, 98, 102t
generic vs. condition-specific instruments, 97
Gross Motor Function Classification System (GMFCS), 95
impacts of, xii
overview, 95
Pediatric QoL Inventory (PedsQL) – CP Module, 98–99, 102t
quality of life measurements generally, 96–97, 102t
Cerebral Palsy Quality of Life Questionnaire for Children, 97
Charcot, Jean-Martin, 41
Cifu, D. X., 125
Classical Test Theory (CTT), 149
Clinical Dementia Rating, 132
Columbia Rating Scale, 10, 12, 15
Common data elements (CDEs), 75–76
Composite Autonomic Symptom Scale (COMPASS), 61
Computer adaptive testing (CAT), 76–77
Content analysis, 6–7, 6t
COPE (Carers of Older People in Europe) Index, 119
Coping with Multiple Sclerosis Caregiving Inventory, 114
CPCHILD (Caregiver Priorities and Child Health Index of Life with Disabilities), 98, 102t
Patient Activity Scale-AD, 83, 84t
QoL-AD, 84t
QoLAS, 84t
QUALID, 84t
QUALIDEM, 83, 84t, 88, 90–91
self-report vs. proxy reports, 83–88, 176
tools generally, 83, 84t
Dementia Behaviour Disturbance Scale, 119–120

Data inputation, 165. See also Expectation maximization (EM)
DCM, 83, 84t
Dementia, QoL measurement in. See also Alzheimer’s disease
ADRQL, 83, 84t
BASQUID, 83, 84t, 87
caregivers, 83–88, 120, 128, 130, 176
CBS, 84t
concepts of, 82–83
data sources, 83–88
DCM, 83, 84t
DEMQoL, 84t, 87, 88–90
DQoL, 83, 84t, 87, 88, 89–90
frontal-temporal lobe, 175
GHQ, carer burden assessment, 114–115, 117–120, 118t
overview, 82, 91
Patient Activity Scale-AD, 83, 84t
QoL-AD, 84t, 87, 88, 89–90, 181–182
QoLAS, 84t
QUALID, 84t
QUALIDEM, 83, 84t, 88, 90–91
self-report vs. proxy reports, 83–88, 176
tools generally, 83, 84t
Dementia Behaviour Disturbance Scale, 119–120

Cultural differences. See Ethnicity, country differences

Data inputation, 165. See also Expectation maximization (EM)
DCM, 83, 84t
Dementia, QoL measurement in. See also Alzheimer’s disease
ADRQL, 83, 84t
BASQUID, 83, 84t, 87
caregivers, 83–88, 120, 128, 130, 176
CBS, 84t
concepts of, 82–83
data sources, 83–88
DCM, 83, 84t
DEMQoL, 84t, 87, 88–90
DQoL, 83, 84t, 87, 88, 89–90
frontal-temporal lobe, 175
GHQ, carer burden assessment, 114–115, 117–120, 118t
overview, 82, 91
Patient Activity Scale-AD, 83, 84t
QoL-AD, 84t, 87, 88, 89–90, 181–182
QoLAS, 84t
QUALID, 84t
QUALIDEM, 83, 84t, 88, 90–91
self-report vs. proxy reports, 83–88, 176
tools generally, 83, 84t
Dementia Behaviour Disturbance Scale, 119–120
Index

DEMQoL, 84t, 87, 88–90
Direct Assessment of Functional Status Scale, 130–131
DISABKIDS CP Disease Module, 98, 102t
DQoL, 83, 84t, 87, 88, 89–90
Dutch PD Society, 13–14
Dysfunctional Behaviour Rating Instrument (DBRI), 131

Effect size statistic overview, 5
Elmstahl questionnaire, 121
Epilepsy, Neuro-QoL Initiative, 76f, 77
EQ-5D
ALS QoL assessment, 180–181
carer burden assessment, 114–115, 129–130
translation of, 139
Ethnicity, country differences
carer burden, 128
PROM translation. See Translation
Ettema, T. P., 83
European ALS-Health Profile Study, 43
European MSA Study Group, 61
EuroQoL, 25–26, 28t, 54, 180–181
Expanded Disability Status Scale (EDSS), 25
Expectation maximization (EM)
method, 166
overview, 165–166, 171
tests of, 167–171, 167t, 168t, 169t, 170t
Ferguson, G. A., 150
Ferguson, L., 150
Frontal-temporal lobe dementia (FTLD), 175
Functional Assessment of MS (FAMS), 26, 28t,
130–131
Functional Limitations Profile. See Sickness Impact Profile
(SIP; Functional Limitations Profile)
Gehrig, Lou. See also Amyotrophic lateral sclerosis (ALS)
General Health Questionnaire, carer burden assessment,
114–115, 117–120, 118t
Geriatric Depression Scale, 132
Global Deterioration Scale, 132
Gross Motor Function Classification System (GMFCS), 95
Guillemin, E., 139, 143
Guttman scaling, 7
Guy's (UK) Neurological Disability Scale (GNDS/UKNDS), 26, 28t
Hawking, Steven, 41
HD-QoL Initiative, 77–78
Health-related (HR) QoL measurement
Huntington's disease, 72–75
Parkinson's disease, 11
quality of life rs., 96, 177–178
questionnaires generally, 177–178, 183–185
Health-related quality of life questionnaire for MS
(HRQoL-MS), 26
Health Utilities Index Mark 2 (HUI2), 117
Hebert, R., 125
Helmholtz, 154
Herdman, M., 142
Higginson, I. J., 83
Hilton, A., 142, 144
Hobson, B., 13–14
Hoehn and Yahr Scale, 10, 12, 15, 130–131
Hospital Anxiety and Depression Scale (HADS), 54, 61–62,
132
HRQoL-MS (health-related quality of life questionnaire for MS), 26
Huntington's disease
common data elements (CDEs), 75–76
computer adaptive testing (CAT), 76–77
HD-QoL Initiative, 77–78
HRQoL measures, 72–75
Neuro-QoL Initiative, 76f, 77
NIH initiatives generally, 75, 76f
overview, 71–72
PROMIS Initiative, 76f, 77
QoL, single-item, 75
SF-36, SIP, 74
SIP data, 74
Unified Huntington's Disease Rating Scale (UHDRS), 73–74
IADL (Instrumental Activities of Daily Living), 131
Impact of Caregiving Scale, 126
Informal carers. See Carer burden
Interval scales described, 2
ISPOR (International Society for Pharameconomics and
Outcomes Research), 139
Item fit residual, 160
Item response theory (IRT)
benefits of, 153
development of, 29, 150–151
limitations of, 154
principles of, 29, 149–150
Rasch analysis vs., 152–154, 152f, 160–162
KATZ questionnaire, 130–131
KIDSCREEN, 98, 101
Knight, B. G., 126–127
Kuder-Richardson (KR-20) test, 4
Lawley, D. N., 150
Lazarsfeld, P. F., 150
Leeds MSQoL scale, 26
Life Satisfaction Questionnaire, 119
Likert, R. A., 29
Longstreth, W., 12
Lord, F. M., 29, 150
Luce, R. D., 154
Masters, G., 29–30, 151–152
Mattis Dementia Rating Scale, 130–131
McGill Quality of Life (MGQoL), 178, 180, 184
McLaughlin, I. E., 99
Medical Outcomes Trust, 140, 142
Mercer, B., 12
Minimal detectable change (MDC), 5
Minimal important difference (MID), 5–6
Mini-Mental State Examination (MMSE), 132
MND Regional Survey, 47
Moniz-Cook, E., 134
Motor neuron disease (MND)
  ALSAQ-5, 46–47
  ALSAQ-40, 44–46, 50–51, 171, 180–181
clinical assessment of, 41–42
health status generic measures, 42–44
Neuro-QoL Initiative, 76f, 77
overview, 41
SF-36 data, 42–43, 116
SIP data, 43–44, 180
MQoL-SIS, 184
MSQoL-54, 26
MS Quality of Life Inventory (MSQLI), 26
MS Walking Scale (MSWS-12), 26
Multiple sclerosis
  Cannabis in Multiple Sclerosis (CAMS) trial, 154–162,
    155t, 156f, 157t, 158f, 160f, 161f
carer burden assessment, 118–119
Functional Assessment of MS (FAMS), 26, 28t,
  130–131
Neuro-QoL Initiative, 76f, 77
SF-36 data, 25–26, 28t
SIP data, 25–26
Multiple Sclerosis Impact Scale (MSIS-29)
  background, 25–26
development, 26–29, 28t, 36
overview, 24–25, 36–37
Rasch analysis. See Rasch analysis
revisions, 29–31, 32f, 33, 33f
version 2, 24, 29–33, 40
Multiple system atrophy, 60–61
Multiple System Atrophy Quality of Life Questionnaire
  (MSA-QoL), 62–64, 67–70
Muscular dystrophy, 76f, 77
National Medical Expenditure Survey, 11
Neurodegenerative disorders, features of, 174–175. See also specific disorders
Neuro-QoL Initiative, 76f, 77
Niven, David, 41
Norman, G., 5–6
Norris ALS Scale, 42
Nottingham Health Profile (NHP), 12
Novick, M. R., 29, 150
Nursing home placement data, 128
Ordinal scales, 2
O’Rourke, N., 125–126, 127, 133
Oxtoby, M., 11
Parkinson’s disease
carer QoL assessment, 120, 130, 131
clinical features of, 175
GHQ, carer burden assessment, 118–119
health-related quality of life issues in, 11
multiple system atrophy, 60–61
Neuro-QoL Initiative, 76f, 77
overview, 10–11
QoL instrument comparison, 181
QoL measurement, challenges in,
  175–176
SF-36 data, 12, 42–43
SIP data, 12
PSP rating by, 52, 54
Parkinson’s Disease Quality of Life Questionnaire (PDQL), 13–14
Parkinson’s Disease Questionnaire (PDQ-39)
data inputation, 165, 166, 171
limitations of, 35
multiple system atrophy, 61–62
overview, 3–4, 14–17, 14r, 16t, 17t, 21r, 167
PSP rating by, 52, 54
Index

Parkinson’s Disease Questionnaire (PDQ-39) (cont.)
SEIQoL-DW vs., 181
Parkinson’s Disease Society study data,
15–16
Parkinson’s Impact Scale (PIMS), 13
Patient Activity Scale-AD, 83, 84
Patient-generated Index instrument (PGI),
179
Patient-reported outcome measures (PROMs). See
Questionnaires
PDQUALIF; 13
Pediatric QoL Inventory (PedsQL) – CP Module, 98–99,
102
Perline, R., 154
Person fit residual, 160
Person Separation Index (PSI), 159
PIXEL, 121
Primary lateral sclerosis, 41
Progressive bulbar palsy (PBP), 41
Progressive muscular atrophy, 41
Progressive supranuclear palsy (PSP), 52–54, 57–59. See
also Parkinson’s disease
PROMIS Initiative, 76f, 77
PROMs (patient-reported outcome measures). See
Questionnaires
PROPATH programme, 12
PSA Association (Europe), 53–54
PSQoL, 52–54, 57–59
PSP Rating Scale, 52
Psychometric methods. See also Item response theory
(IRT); Rasch analysis
advantages, limitations of, 29, 33–36
Classical Test Theory (CTT), 149
development of, 29, 36
limitations of, 149, 160–162
principles of, 29, 147–149
range of evidence, 29
RMI analysis, 154–162, 155f, 156f, 158f, 160f, 161f
QoL-AD, 84f, 87, 88, 89–90, 181–182
QoLAS, 84f
QUALID, 84f
QUALIDEM, 83, 84f, 88, 90–91
Quality of life (QoL) measurement
challenges in, 175–176
concepts of, 82–83, 177
healthy subjects, 182
importance of, 96
individualized, 174, 179, 185
instruments, applications of, 176–177
response shift impact, 182–184
Questionnaires
change, sensitivity to, 5–7, 6f
disease, domain-specific, 178–179
existential, 178
generic, 12–13, 25–26, 97, 114–115
health-related QoL, 177–178, 183–185
individualized, 174, 179
measures, selection of, 7–8
overview, 1, 8, 11–12, 17
reliability in, 4–5
scales in, 1–3
self-report vs. proxy report, 97–98, 176
translation of. See Translation
types of, 177
validity in, 3–4, 5–7, 6f, 183
Rankin, E. D., 133
Rasch, G., 29, 147, 151–152
Rasch analysis
benefits of, 24–25, 33–36, 153–154,
160–162
development of, 29, 151–152
IRT rs., 152–154, 152f, 160–162
limitations of, 154
methodology, 29–30
overview, 4, 7, 147
principles of, 29, 149–150
range of evidence, 29
RMI, 154–162, 155f, 156f, 157f, 158f, 160f, 161f
Ratio scales described, 2–3
Ready, R. E., 87, 88
Reliability (general). See also specific scales
internal, 4
interobserver (inter-rater), 5
test-retest, 4–5
Response shifts, 182–184
Revicki, D., 5–6
Richardson, M., 150
Rivermead Mobility Index (RMI), 148, 154–162, 155f, 156f,
157f, 158f, 160f, 161f
Roud, H., 125
Royal Children’s Hospital cerebral palsy study,
99–100
Rubenstein, L., 11
Sarah Matheson Trust for MSA (SMT) study, 62–63
Schedule for Individual Quality of Life (Direct Weighted version) (SEIQoL-DW)
ALS, 44, 179, 180, 184
Alzheimer's disease, 181–182
limitations of, 184
overview, 44, 179
PDQ-39 vs., 181
response shift impact, 182–183
Schedule for the Evaluation of Individual Quality of Life (SEIQoL), 114–115, 129–130, 179, 182
Schölzel-Dorenbos, C. J. M., 88
Schwab and England Scale, 10
Selegiline, 10
SF-12
overview, 115–116, 116’t
reliability, 116
validity, 116–117
SF-36 (36-Item Short Form Health Survey)
ALS measurement, 42–43, 116, 180–181
Alzheimer's disease, 116, 117
carer burden assessment, 114–115, 117, 133–134
Huntington's disease, 74
limitations of, 35
MND/ALS, 42–43, 116
multiple sclerosis, 25–26, 28’t
multiple system atrophy, 61
overview, 115–116, 116’t, 178
Parkinson's disease, 12, 42–43
precision, 117
reliability, 116
translation of, 139
validity, 116–117
Sickness Impact Profile (SIP, Functional Limitations Profile)
Huntington's disease, 74
MND/ALS, 43–44, 180
multiple sclerosis, 25–26
Parkinson's disease, 12
SIP/ALS-19, 44
Skrutkowski, M., 142, 144
Sloane, P. D., 88
SMS-ADL (Activities of Daily Living Subscale of the SCOPA-Motor scale), 131
Sperber, A. D., 144
Spurlock, W. R., 125
Steele–Richardson–Olszewski syndrome, 52
Stevens, S. S., 153
Stone, 151–152
Stroke, 76f, 77, 119
Swaine-Verdier, A., 144
Thurstone, L. L., 29, 150
Translation
assessors (raters), 144
documentation, 144
equivalence in, 141–142, 143’t, 144
forward and back, 141, 144
methods, 140–141
one-way, 140–141
overview, 139–140, 145
panel, 141
quality, 141–142, 143’t, 144
translators, 142–144
types of, 140
Tucker, L. R., 150
Tufts Quantitative Neuromuscular Exam (TQNE), 42–44
Tukey, J. W., 154
Tuokko, H. A., 127, 133
UK MND Association study, 45
Unified Huntington's Disease Rating Scale (UHDRS), 73–74
Unified Multiple System Atrophy Rating Scale (UMSARS), 61
Unified Parkinson's Disease Rating Scale (UPDRS), 10, 15, 130–131
Validity (general). See also specific scales
concurrent, 4
construct, 3
content, 3
convergent, 3
criterion, 3–4
discriminant, 3
face, 3
longitudinal, 5–7, 6’t
overview, 3, 183
predictive, 4
Victorian Cerebral Palsy Register study, 99–100
Vitaliano, P. P., 114
Ware, J., 6–7
Whitehouse, P., 83
Whitlatch, C. J., 126, 128
Index

WHOQoL, 114–115
Wild, D., 140, 141, 144
Wright, B. D., 29–30, 151–152

Zarit Burden Interview (ZBI)
carer variables, 128–130
construct validity, 126–127
cut-off scores, 133

t, 133–134
overview, 115, 117, 121, 122, 133–134
patient variables, 130–132
psychometrics, 125
reliability, 125–126
responsiveness to change, 133
validity, 127–132
versions, 121–125, 122

More information